IRIS

An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.

Ropinirole-containing hydrophilic/liphilic polymeric matrix dosage formulation

MAGGI, LAURETTA;CONTE, UBALDO;
2000-01-01

Abstract

An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
2000
Chemistry & Analysis covers research on natural and laboratory syntheses, chemical structure, structure-function relationship, isolation and analyses of biologically significant molecules, medicinal and food chemistry. Technical material describing crucial chemical methods in biochemical analysis and research is also placed in this category. Resources covering general biochemistry and natural metabolic pathways are excluded.
EP1272167B1
ELETTRONICO
Inglese
Internazionale
POLYMER; MATRIX; DOSAGE FORMULATION
Patente granted by the European Patent Office end in the following countries: EP1272167 (B1) WO0178688 (A1) US2011177167 (A1) US2007264336 (A1) US7927624 (B2) US2010003320 (A1) US2003180359 (A1) SI1272167 (T1) PT1272167 (E) PL365837 (A1) PL202689 (B1) NZ521902 (A) NO20024919 (A) MXPA02010151 (A) KR20090094406 (A) KR20080047630 (A) KR20070065922 (A) JP2009029813 (A) JP2003530423 (A) IL152184 (A) HU0300530 (A2) HK1053602 (A1) ES2307608 (T3) EP2343060 (A1) EP1681051 (A1) DK1272167 (T3) CZ20023415 (A3) CN1427717 (A) CN1198598 (C) CA2405508 (A1) CA2405508 (C) BR0110038 (A) AU2009230759 (A1) AU2005201805 (A1) AU2005201805 (B2) AU779623 (C) AU779623 (B2) AT401867 (T) AR030557 (A1) On this patent the product REQUIP was lauched. Requip® (ropinirole 2, 4, 8 mg) is a once daily formulation for Parkinson’s disease which was developed in partnership with GlaxoSmithKline's. The new Requip® once daily formulation uses the patented Geomatrix™ technology and is designed to provide smoother blood levels of ropinirole without the peaks and troughs that multiple daily doses invariably deliver. In addition, the new Requip® once daily formulation offers physicians and patients a simpler titration schedule compared with the recommended titration schedule for immediate-release Requip®, which is dosed three times a day. Requip® Once-a-day was filed for approval at the end of 2005 in Europe, and, in March 2007, the French Ministry of Health was the first major European regulator to grant authorisation (as ‘‘Requip® LP’’). GSK launched Requip® LP in France in January 2008 and it is currently approved in 23 countries in Europe and has now been launched in France, Germany, UK and a number of other European markets.
6 Brevetti::6.1 Brevetto
none
Maggi, Lauretta; Conte, Ubaldo; Grenier, Pascal; Vergnault, Guy
info:eu-repo/semantics/patent
285
4
6.1 Brevetto
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/202773
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact